Chugai Pharmaceutical CoCHGCY +0.13%92 EBITDA Margin % is 49.34% as of Mar. 2026, which is 27% above its 10-year median of 38.92. GuruFocus rates CHGCY with a GF Score™ of 92/100 and a GF Value™ of $24.28 (Fairly Valued). The stock has 1 warning sign investors should review. Among 955 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 96.13% on this metric.
Chugai Pharmaceutical Co (OTCPK:CHGCY) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Chugai Pharmaceutical Co EBITDA Margin % Related Terms
Chugai Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHGCY vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (CHGCY) has a EBITDA Margin % of 49.34% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chugai Pharmaceutical Co and its competitors. This is 27% above median its historical median of 38.92. Over the past decade, Chugai Pharmaceutical Co's EBITDA Margin % has ranged from 15.16 to 48.03. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #37 out of 955 companies in the Drug Manufacturers industry, placing it in the top 3.9%.
Is Chugai Pharmaceutical Co's EBITDA Margin % too high?
Chugai Pharmaceutical Co's current EBITDA Margin % of 49.34% is 27% above median its 10-year median of 38.92. Over the past 10 years, this metric has ranged from a low of 15.16 to a high of 48.03. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Chugai Pharmaceutical Co's value of 49.34% is 298.2% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #37 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chugai Pharmaceutical Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #37 out of 955 companies for EBITDA Margin %. This places Chugai Pharmaceutical Co in the top 4% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Chugai Pharmaceutical Co's value of 49.34% is 298.2% above this benchmark. Historically, Chugai Pharmaceutical Co's own EBITDA Margin % has ranged from 15.16 to 48.03 over the past decade. While the company's 10-year median is 38.92 vs. the industry median of 12.39, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current EBITDA Margin % of 49.34% is 298.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current EBITDA Margin % is 49.34%, which is 27% above median its own 10-year median of 38.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCY) is currently considered Fairly Valued. The stock's GF Value™ is $24.28, compared to a current price of $22.99 — trading 5.3% below its estimated fair value. The current EBITDA Margin % is 49.34%, which is 27% above median its 10-year median of 38.92 and 298.2% above the Drug Manufacturers industry median of 12.39. Chugai Pharmaceutical Co's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCY), the current EBITDA Margin % is 49.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (CHGCY) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of $22.99 is trading 5.3% below its estimated GF Value™ of $24.28.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for CHGCY:
EBITDA Margin %: 49.34% (27% above median its 10-year median of 38.92)
GF Value™: $24.28 vs. price of $22.99 (5.3% below fair value)
Industry Position: 298.2% above the Drug Manufacturers median (#37 of 955)
No single metric tells the full story. See the CHGCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
92GF Score
Get the complete analysis for CHGCY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHGCY has been successfully added to your 
